Bear Stearns Cuts AstraZeneca Outlook

Analyst Alexandra Hauber says she'll now assume a smaller market size for the drug maker's new lung cancer treatment

Bear Stearns cut estimates on AstraZeneca (AZN ).

To continue reading this article you must be a Bloomberg Professional Service Subscriber.